+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives

Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives

Patient 2019:

Biologic therapies are cost effective for active rheumatoid arthritis but have adverse effects and are costly. Tapering of biologics is emerging as an important consideration when sustained remission is achieved. Recent trials have highlighted the clinical feasibility of tapering, but there is little evidence on how proposed tapering would be received by patients. The aim of this study was to explore factors influencing hypothetical decisions of patients with rheumatoid arthritis on tapering their biologics and their perspectives on remission and flare when considering the possibility of tapering. Patients with rheumatoid arthritis with diverse experiences of biologics with different modes of administration were purposively sampled to participate in one of six focus groups (n = 43) or an individual interview (n = 2). Transcripts were analyzed using inductive thematic analysis. Five overarching themes on what influences a participant's decision to taper their biologic were identified. First, participants were fearful of uncertain outcomes of tapering, especially flare and joint damage. Second, participants prioritized quality of life from continuing biologics over the risk of adverse effects. Third, tapering biologics was seen as providing relief from the inconvenience of taking biologics regularly. Fourth, participants wanted assurance of prompt access to healthcare if their rheumatoid arthritis were to flare when tapering. Fifth, preferences for involvement in decision making varied, but fulfilling information needs was desired to aid a patient's preferred role in decision making on tapering. This study provides novel insight into the perspectives of patients with rheumatoid arthritis on tapering biologics when sustained remission is achieved at a crucial juncture in global affordability for healthcare systems. These patient perspectives can inform the planning of decision aids and clinical trials of decision-making processes when tapering is proposed.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 069583695

Download citation: RISBibTeXText

PMID: 31802391

Related references

OP0258Optimizing Therapy in Inflammatory Arthritis: Prediction of Relapse after Tapering or Stopping Dmards/ Biologic Agents by Ultrasonographic Assessment in Rheumatoid Arthritis Patients Who Achieved Clinical Remission. Annals of the Rheumatic Diseases 75(Suppl 2): 156.1-156, 2016

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Annals of the Rheumatic Diseases 75(8): 1428-1437, 2016

Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology 54(8): 1408-1414, 2015

PARE0019Patient Perspectives on Footwear in Rheumatoid Arthritis A Patient-Led Qualitative Study. Annals of the Rheumatic Diseases 74(Suppl 2): 1364.2-1364, 2015

Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis. Patient 12(3): 297-305, 2019

Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. Patient Preference and Adherence 10: 1079-1090, 2016

Care Needs for Rheumatoid Arthritis from Patient Perspectives: A Qualitative Study from Singapore General Hospital. Value in Health 17(7): A775, 2014

Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives. Arthritis Care and Research 2019:, 2019

FRI0520Predictive Value of Subclinical Synovitis Detected by Doppler Ultrasound in Relation to Flare in Patients with Juvenile Idiopathic Arthritis Treated with Biologic Therapy After Tapering Biologic Therapy; Preliminary Results. Annals of the Rheumatic Diseases 74(Suppl 2): 616.3-617, 2015

Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study. Arthritis Care and Research 71(1): 80-87, 2019

Patients' Perspectives on Tapering of Chronic Opioid Therapy: A Qualitative Study. Pain Medicine 17(10): 1838-1847, 2016

Patient-reported fatigue in patients with rheumatoid arthritis who commence biologic therapy: a longitudinal study. Peerj 7: E6771, 2019

AB1078-HPRTelephone Follow-Up, Standardized To The Initiation of Biologic Therapy of Patients with Rheumatoid Arthritis (RA) in A Specific Unit of Biologic Therapy. Pilot Study. Annals of the Rheumatic Diseases 75(Suppl 2): 1300.2-1300, 2016

The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study. Musculoskeletal Care 7(3): 194-209, 2009

The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmunity Reviews 16(12): 1185-1195, 2017